REFERENCES
- Ettinger D S. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 1995; 22: 6–18, [PUBMED], [INFOTRIEVE]
- Culy C R, Bhana N, Plosker G L. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs 2001; 3: 441–449, [PUBMED], [INFOTRIEVE], [CSA]
- Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology 1992; 49: 279–285, [PUBMED], [INFOTRIEVE]
- Safonova S A, Gershanovich M L, Punanov Iu A, et al. [Evaluation of the anti-emetic effectiveness of two drug formulations of ondansetron in combined chemotherapy for children with malignant tumors] [Article in Russian]. Vopr Onkol 1999; 45: 424–428, [PUBMED], [INFOTRIEVE], [CSA]
- White L, Daly S A, McKenna C J, et al. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimen given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 2000; 17: 445–455, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhang P, Feng F, He Y, et al. [Nausea disintegrating buccal tablet in the prevention of gastrointestinal reaction induced by anticancer drugs] [Article in Chinese]. Zhonghua Zhong Liu Za Zhi 2002; 24: 504–507, [PUBMED], [INFOTRIEVE], [CSA]
- Lehoczky O, Udvary J, Pulay T. Freeze dried ondansetron: first observations with fast dissolving oral antiemetic Zofran Zydis for the prophylaxix of the cisplatin-induced emesis in gynecological cancer patients. Neoplasma 2002; 49: 126–128, [PUBMED], [INFOTRIEVE], [CSA]
- Bleiberg H, Van Belle S, Paridaens R. Compassionate use of tropisetron in patients at high risk of sever emesis. Ann Oncol 1993; 4: 43–45, [PUBMED], [INFOTRIEVE]
- Özkan A, Yıldız İ, Yüksel L, et al. Tropisetron (Navoban®) in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Jpn J Clin Oncol 1999; 29: 92–95, [CROSSREF], [CSA]
- Uysal K M, Olgun N, Sarıalioğlu F. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients. Turk J Cancer 1999; 41: 207–218, [CSA]
- Schnell F M. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003; 8: 187–198, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Köseoğlu V, Kürekçi A E, Sarıcı U, et al. Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 1998; 157: 806–810, [CROSSREF], [CSA]
- Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 1999; 16: 101–108, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gralla R J, Osoba D, Kris M G, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 1999; 17: 2971–2994, [PUBMED], [INFOTRIEVE]
- Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805–810
- Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994; 30: 1083–1088, [CROSSREF]
- Marty M, Kleisbauer J P, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis?. Anti-Cancer Drugs 1995; 6: 15–21, [PUBMED], [INFOTRIEVE], [CSA]
- Perez E A. Overview: oral granisetron (Kytril tablets): prophylaxis for chemotherapy induced nausea and vomiting. Semin Oncol 1995; 22: 1–2, [PUBMED], [INFOTRIEVE]
- Friedman C J, Burris H A, III, Yocom K, et al. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist 2000; 5: 136–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Spector J I, Lester E P, Chevlen E M, et al. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy. Oncologist 1998; 3: 432–438, [PUBMED], [INFOTRIEVE]
- Balfour J A, Goa K L. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997; 54: 273–298, [PUBMED], [INFOTRIEVE]
- Holdsworth M T, Raisch D W, Duncan M H, et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother 1995; 29: 16–21, [PUBMED], [INFOTRIEVE], [CSA]
- Stevens R F. The role of ondansetron in paediatric patients: a review of three studies. Eur J Cancer 1997; 27: 20–22
- Small B E, Holdsworth M T, Raisch D W, et al. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 2000; 22: 125–132, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Benoit Y, Hulstaert F, Vermylen C, et al. Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol 1995; 25: 457–462, [PUBMED], [INFOTRIEVE]
- Hachimi-Idrisis S, De Schepper J, Maurus R. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy. Eur J Cancer 1993; 29: 854–856
- Pinkerton C R, Williams D, Wootton C, et al. 5-HT3 antagonist ondansetron—an effective outpatient antiemetic in cancer treatment. Arch Dis Child 1990; 65: 822–825, [PUBMED], [INFOTRIEVE]
- Alvarez O, Freeman A, Bedros A, Call S K, et al. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995; 17: 145–150, [PUBMED], [INFOTRIEVE], [CSA]
- Cohen I J, Zehavi N, Buchwald I, et al. Oral ondansetron: an effective ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol 1995; 12: 67–72, [PUBMED], [INFOTRIEVE], [CSA]
- Komado Y, Matsuyama T, Takoa A, et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukemia receiving emetogenic chemotherapy. Eur J Cancer 1999; 35: 1095–1101, [CROSSREF]
- Liaw C C, Wang C H, Chang H K, et al. Gender discrepancy observed between chemotherapy-induced emesis and hiccups. Support Care Cancer 2001; 9: 435–441, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Perez E A, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind randomized parallel study. J Clin Oncol 1998; 16: 754–760, [PUBMED], [INFOTRIEVE]
- Anastasia P J. Effectiveness of oral 5-ht3 receptor antagonists for emetogenic chemotherapy. Oncol Nurs Forum 2000; 27: 483–493, [INFOTRIEVE], [CSA]